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In utero environmental adaptation may predispose to lifelong morbidity. Organisms ﬁne-tune gene expression to achieve
environmental adaptation by epigenetic alterations of histone markers of gene accessibility. One example of epigenetics is how
uteroplacental insuﬃciency-induced intrauterine growth restriction (IUGR), which predisposes to adult onset insulin resistance,
decreases postnatal IGF-1 mRNA variants and the gene elongation mark histone 3 trimethylation of lysine 36 of the IGF-1 gene
(H3Me3K36). Limitations in the study of epigenetics exist due to lack of a primary transgenic epigenetic model. Therefore we
examinedtheepigeneticproﬁleofinsulin-likegrowthfactor1(IGF-1)inawell-characterizedratmodelofmaternalhyperglycemia
to determine if the epigenetic proﬁle of IGF-1 is conserved in disparate models of in utero adaptation. We hypothesized that
maternal hyperglycemia would increase IGF-1 mRNA variants and H3Me3K36. However maternal hyperglycemia decreased
hepatic IGF-1 mRNA variants and H3Me3K36. This ﬁnding is intriguing given that despite diﬀerent prenatal insults and growth,
both maternal hyperglycemia and IUGR predispose to adult onset insulin resistance. We speculate that H3Me3K36 of the IGF-
1 gene is sensitive to the glucose level of the prenatal environment, with resultant alteration of IGF-1 mRNA expression and
ultimately vulnerability to adult onset insulin resistance.
1.Introduction
An adverse in utero nutritional environment predisposes to
lifelong morbidity [1]. One way an organism can adapt
to its adverse in utero nutritional environment is through
ﬁne-tuning gene expression. The modiﬁcation through
which reprogramming of gene expression occurs is called
epigenetics. The epigenetic proﬁle consists of a series of
DNA and histone modiﬁcations that allow increased or
decreasedaccessoftranscriptionmachinerytoDNAforﬁne-
tuning of gene expression. Fine-tuning of gene expression
and environmental adaptation can occur through alternate
promoter or exon usage.
IGF-1 exempliﬁes a classic gene that undergoes epige-
netic regulation [2, 3]. IGF-1 is a gene whose protein is
responsible for postnatal growth and is involved in insulin
sensitivityandcanbetranscribedfromoneoftwopromoters
and with alternative splicing of exon 5 (Figure 1). Regulation
of IGF-1 variant expression is in part due to alteration of
the pattern of DNA methylation and histone modiﬁcations
aroundthegeneandissensitivetotheperinatalenvironment
[3–5].
Hepatic IGF-1 mRNA levels largely impact serum IGF-1
levels and are heavily modulated by epigenetics in the setting
of intrauterine growth restriction (IUGR) [3, 6]. IUGR
causes fetal hypoglycemia, decreases postnatal growth, and
predisposes to adult onset insulin resistance, both of which
are modulated by IGF-1. Observation of the epigenetic
proﬁle of the IGF-1 gene from promoter 1 through the 3 
untranslated region (UTR) at day of life (DOL) 21, prior to
the onset of insulin resistance, revealed persistent decrease
in histone 3 trimethylation of lysine 36 (H3Me3K36) [3],
a histone mark that is associated with gene elongation [7–
9]. Although the eﬀects of IUGR on the epigenetic proﬁle
of the IGF-1 gene and H3Me3K36 in particular are known,
further study of the epigenetic proﬁle of the IGF-1 gene has2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 1: Genomic and mRNA variants of the rat IGF-1 gene.
Exons are shown as boxes and introns as lines. IGF-1A lacks exon
5, while IGF-1B contains exon 5. Transcription of IGF-1A and IGF-
1B may begin from within either of promoter 1 (P1) or promoter 2
(P2).
been limited due to lack of a primary transgenic epigenetic
model. Therefore we sought an alternative method to study
the epigenetic proﬁle of IGF-1, using a disparate model to
IUGR to determine whether the vulnerability of H3Me3K36
to perinatal insults is conserved.
The model we chose to study epigenetic proﬁle of the
IGF-1 gene is a well-characterized model of streptozotocin-
(STZ-) induced maternal hyperglycemia [10]. Maternal hy-
perglycemia was chosen because the in utero eﬀects of
maternal hyperglycemia on the fetus are quite diﬀerent from
those seen in the setting of IUGR. In humans, maternal
hyperglycemia often generates large for gestational age
infants and increases IGF-1 serum levels at birth [11–13],
yet it still predisposes to alterations in postnatal growth
and to adult onset insulin resistance. In this rat model of
maternalhyperglycemia,oﬀspringofhyperglycemicmothers
(OHMs) have the same average birth weight but with greater
numbers of larger and smaller pups than oﬀspring from
control (CON) mothers, OHM males gain less weight after 2
monthsofage,andOHMmalesdevelopinsulinresistanceby
6 months of age [10]. DOL 21 was chosen for our epigenetic
proﬁle evaluation of the IGF-1 gene because it precedes
the confounders of adolescence, weight gain, and insulin
resistance.
We hypothesized that maternal hyperglycemia in rats
would increase oﬀspring serum IGF-1 levels, hepatic IGF-1
mRNA variants, and epigenetic markers of IGF-1 associ-
ated with gene elongation. Speciﬁcally, rat maternal hyper-
glycemia would decrease oﬀspring promoter DNA methy-
lation and alter multiple markers of the histone code from
promoter 1 through the 3 UTR of the IGF-1 gene including
increased H3Me3K36. Further, because of their increased
risk of development of insulin resistance in adulthood, we
hypothesized that these alterations of IGF-1 will be worse in
males.
2.MaterialsandMethods
2.1. Animals. Frozen rat serum and liver were generously
given by Dr. Segar at the University of Iowa. Animals from
diﬀerent litters were used for each experiment with an
n = 3–6 per sex and per treatment for a total of 24 animals
for serum glucose and IGF-1 experiments and a total of 15
animals for liver mRNA and epigenetic proﬁle experiments.
Animal procedures were previously described [10]. In brief,
there was no diﬀerence in litter size between OHM and CON
[10]. Oﬀspring birth weights did not diﬀer between OHM
and CON, though with greater variability among OHM such
that there were more large and small pups. Single serum
glucose was determined at necropsy using the LifeScan One
Touch Ultra Blood Glucose Monitoring System (LifeScan
I n c ,M i l p i t a s ,C A ) ,f o rat o t a lo fn = 6 per sex per treatment.
2.2. Enzyme Immunoassay. Serum from DOL 21 OHM was
generously given by Dr. Segar at the University of Iowa.
Serum IGF-1 levels at DOL 21 were measured in triplicate
withtheQuantikineMouse/RatIGF-1enzymeimmunoassay
kit following the manufacturer’s protocol (R&D Systems,
Inc., Minneapolis, MN, USA).
2.3. RNA Isolation. Total RNA was isolated from frozen
liver at DOL 21 as previously described [14] using the
Nucleospin RNAII kit (Machery-Nagel, Bethlehem, PA,
USA), including DNase I treatment. RNA was quantitated
with a spectrophotometer and checked by gel electrophoresis
for integrity. The cDNA was synthesized from 1µgR N A
using the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA) per manufactur-
ers’ protocol.
2.4. Real-Time Reverse Transcriptase Polymerase Chain
Reaction (RT-PCR). Real-time RT-PCR was performed as
described previously [14]. Primers and probes were the same
as used previously [3]. Semiquantitative real-time RT PCR
quantiﬁcation was then performed using glyceraldehydes-3
phosphate dehydrogenase (GAPDH) as an internal control,
as Ct values of GAPDH did not diﬀer between CON and
OHM animals [15]. Relative quantiﬁcation of PCR products
was based on diﬀerences between GAPDH and the target
using the comparative Ct method (TaqMan Gold RT-PCR
manual; PE Biosystems, Foster City, CA, USA).
2.5. Chromatin Immunoprecipitation (ChIP) Assay and Real-
Time PCR. ChIP with 1µL anti-H3AcK14, anti-H3Me2K4,
anti-H3Me3K4 (Millipore Upstate, Charlottesville, VA,
USA), and anti-H3Me3K36 (Abcam, Cambridge, MA, USA)
was performed as described previously for chromatin from
DOL 21 livers [3, 14]. Chromatin equivalent to 100µgD N A
based on A260 absorption was used in each immunoprecip-
itation (IP) reaction. After puriﬁcation from IP chromatin,
DNA was determined with a standard curve with SYBR
Safe DNA gel stain (Molecular Probes, Eugene, OR, USA).
The SYBR Safe ﬂuorescence was measured using a Tecan
platereader(GeniosPro-Basicw/oFP;TecanAustriaGmbH,
Grodig, Austria) and Magellan V 6.2 software (Tecan). DNA
fragmentscontainingIGF-1site-speciﬁcsequencesincluding
the seven regions of interest (P1, P2, exon 3, exon 4, exon
5, and proximal and distal 3 untranslated region (UTR) of
exon 6) of the IGF- 1 gene were quantiﬁed by real-time PCR
[3]. Primer and probe sequences are the same as described
previously [3], and for exon 3 the following primers
were used: forward primer AGACGGGCATTGTGGATGA,
reverse primer TCCTGGGTGTGCCTTTGAC, and probeJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 2: Maternal hyperglycemia did not decrease oﬀspring glucose and serum IGF-1 levels. (a) DOL 21 OHM glucose levels for female
and male oﬀspring, CON in white bars and OHM in grey bars. (b) DOL 21 OHM serum IGF-1 levels for female and male oﬀspring, CON
in white bars and OHM in grey bars. Serum glucose and IGF-1 levels were expressed as mean ± standard error of the mean, n = 6C O N
female, n = 6 OHM female, n = 6C O Nm a l e ,a n dn = 6 OHM male.
TGTTGCTTCCGGAGCT. Relative quantiﬁcation of PCR
products was based on value diﬀerences between the target
and intergenic control using the comparative Ct method
[15]. An intergenic region upstream of the IGF-1 gene was
chosen as a well-characterized nontranscribing region of
DNA that contains the histone marks of interest in this series
of experiments as described by Fu et al. [3]. The distribution
patternofhistonemodiﬁcationsalongIGF-1wasdetermined
by looking at the seven sites as indicated previously and
expressed as a percentage of the values obtained for P1.
2.6. Bisulﬁte Modiﬁcation. Bisulﬁte modiﬁcation was per-
formed as described previously using the primers as
described previously [3, 14]. PCR conditions were 95◦Cf o r
10 minutes, then 94◦C for 30 seconds, annealing at either
53◦Co r5 4 ◦C for 30 seconds depending on the primers,
and 72◦C for 30 seconds, for 35 cycles. PCR products were
cloned into the vector for pSC-A (Stratagene, Cedar Creek,
TX, USA). Six to eight colonies from each PCR cloning
reaction were inoculated into SeqPrep 96 well plates (Edge
BioSystems, Gaithersburg, MD, USA). The plasmid DNA
was prepared using the SeqPrep 96 Plasmid Prep Kid (Edge
BioSystems) and sequenced according to protocol using
the BigDye Terminator v3.1 Cycle Sequencing kit (Applied
Biosystems) with M13 forward or reverse primers.
2.7. Statistics. Data were presented as a mean ± standard
error (SE) percent of control or of P1. ANOVA (Fisher’s
protectedleast-signiﬁcantdiﬀerence)andStudent’sunpaired
t-test were used for real-time RT PCR. Student’s 2-tailed t-
test was used for DNA methylation. A value of P<0.05 was
considered to be statistically signiﬁcant.
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Figure 3: Maternal hyperglycemia decreased hepatic IGF-1 mRNA
variants in males. DOL 21 OHM hepatic mRNA variants were
expressedasmean ±standarderrorofthemeanrelativetoGAPDH,
for female (F) and male (M) oﬀspring, CON in white bars and
OHM in grey bars, n = 4C O Nf e m a l e ,n = 3 OHM female, n = 5
CON male, and n = 3 OHM male. ∗P<0.05.
3. Results
3.1.HepaticIGF-1mRNAandSerumLevels. No diﬀerencein
serum glucose and IGF-1 levels was detected between OHM
and CON at DOL 21 (Figure 2). Maternal hyperglycemia
signiﬁcantly decreased male promoter 1 (P1), promoter 2
(P2), and IGF-1A mRNA levels (Figure 3). No changes were
seen in female IGF-1 mRNA levels (Figure 3).
3.2. Hepatic IGF-1 Histone Code. Seven sites along the hep-
atic IGF-1 gene were analyzed for four histone H3 covalent
modiﬁcations in the control group to determine a normal
histone code along the hepatic rat IGF-1 gene. These same4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
P
1
P
2
E
x
o
n
3
E
x
o
n
4
E
x
o
n
5
P
r
o
x
i
m
a
l
3
 
U
T
R
D
i
s
t
a
l
3
 
U
T
R
Female CON
H
i
s
t
o
n
e
m
o
d
i
ﬁ
c
a
t
i
o
n
a
s
%
o
f
P
1
0
500
1000
1500
2000
acK14 me2K4
me3K4 me3K36
∗∗∗∗
∗∗∗∗
∗∗∗∗
∗∗∗∗
∗∗∗∗
∗∗∗∗
∗∗∗∗
∗∗∗∗
∗∗∗∗
∗∗
∗∗
∗∗ ∗
∗∗
∗
∗
∗
∗∗∗ ∗∗∗
(a)
P
1
P
2
E
x
o
n
3
E
x
o
n
4
E
x
o
n
5
P
r
o
x
i
m
a
l
3
 
U
T
R
D
i
s
t
a
l
3
 
U
T
R 0
50
100
150
200
Female OHM
H
i
s
t
o
n
e
m
o
d
i
ﬁ
c
a
t
i
o
n
a
s
%
o
f
c
o
n
t
r
o
l
acK14 me2K4
me3K4 me3K36
∗
(b)
Male CON
0
500
1000
1500
2000
P
1
P
2
E
x
o
n
3
E
x
o
n
4
E
x
o
n
5
P
r
o
x
i
m
a
l
3
 
U
T
R
D
i
s
t
a
l
3
 
U
T
R
H
i
s
t
o
n
e
m
o
d
i
ﬁ
c
a
t
i
o
n
a
s
%
o
f
P
1
acK14 me2K4
me3K4 me3K36
∗∗∗∗ ∗∗∗∗
∗∗∗∗ ∗∗∗∗
∗∗∗∗ ∗∗∗∗
∗∗∗∗
∗∗∗∗
∗∗∗
∗∗∗
∗∗
∗ ∗
∗
∗ ∗ ∗
(c)
#
acK14 me2K4
me3K4 me3K36
0
50
100
150
200
Male OHM
P
1
P
2
E
x
o
n
3
E
x
o
n
4
E
x
o
n
5
P
r
o
x
i
m
a
l
3
 
U
T
R
D
i
s
t
a
l
3
 
U
T
R
H
i
s
t
o
n
e
m
o
d
i
ﬁ
c
a
t
i
o
n
a
s
%
o
f
c
o
n
t
r
o
l
∗
∗ ∗ ∗
∗
(d)
Figure 4:MaternalhyperglycemiadecreasedH3Me3K36alongthelengthoftheIGF-1geneinmales.(a)FemaleIGF-1histonemodiﬁcations
incontrolanimalsexpressedasameanpercentofP1 ±standarderrorofthemean.(b)FemaleIGF-1histonemodiﬁcationsinOHManimals
expressed as a mean percent of gender matched control values ± standard error of the mean. (c) Male IGF-1 histone modiﬁcations in control
animals expressed as a mean percent of P1 ± standard error of the mean. (d) Male IGF-1 histone modiﬁcations in OHM animals expressed
as a mean percent of gender matched control values ± standard error of the mean, n = 4C O Nf e m a l e ,n = 3 OHM female, n = 5C O N
male, and n = 3 OHM male. ∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001; ∗∗∗∗P<0.0001.
seven sites were analyzed in OHM to determine the eﬀect
of maternal hyperglycemia on these sites. Each modiﬁcation
in both CON and OHM groups was normalized to the
intergenic region. Each modiﬁcation was then expressed as
ap e r c e n to fP 1 .
At DOL 21, acetylation at lysine 14 is increased at P2
and then decreased along the rest of the IGF-1 gene relative
to P1 in both genders. Similarly, di- and trimethylation are
increased at P2 and decreased along the remainder of the
IGF-1 gene in both genders. Trimethylation of lysine 36 was
increased at all sites relative to P1 in both genders (Figure 4).
These seven sites were also analyzed in the oﬀspring
of hyperglycemic dams. Results were presented relative to
controlswherecontrolswereconsideredtobe100%.AtDOL
21,maternalhyperglycemiaincreasedacetylationoflysine14
in males distally, with no change seen in females. No change
was seen in either di- or trimethylation of lysine 4 in either
gender. Maternal hyperglycemia decreased trimethylation of
lysine 36 throughout the IGF-1 gene in males, and at exon 4
in females (Figure 4).
3.3. IGF-1 P1 Methylation. Twelve CpG sites within P1
of IGF-1 were analyzed for methylation. Maternal hyper-
glycemia signiﬁcantly increased methylation in females at
sites −260 and −143. No diﬀerence was seen in methylation
at P1 in males (Figure 5).
3.4. IGF-1 P2 Methylation. Six CpG sites within P2 of IGF-
1 were analyzed for methylation. No signiﬁcant diﬀerences
were seen in either gender (Figure 5).J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
0
25
50
75
100
125
Female P1 CpG methylation
∗
∗
C
p
G
m
e
t
h
y
l
a
t
i
o
n
(
%
)
−
5
2
8
−
5
2
3
−
4
7
0
−
3
0
2
−
2
6
0
−
2
3
1
−
1
4
3
−
8
6
−
3
1
−
2
9
1
3
2
2
CON
OHM
(a)
0
10
20
30
Female P2 CpG methylation
C
p
G
m
e
t
h
y
l
a
t
i
o
n
(
%
)
CON
OHM
−231 −142 −133 −112 −70 −41
(b)
0
25
50
75
100
125
Male P1 CpG methylation
C
p
G
m
e
t
h
y
l
a
t
i
o
n
(
%
)
CON
OHM
−
5
2
8
−
5
2
3
−
4
7
0
−
3
0
2
−
2
6
0
−
2
3
1
−
1
4
3
−
8
6
−
3
1
−
2
9
1
3
2
2
(c)
0
10
20
30
Male P2 CpG methylation
C
p
G
m
e
t
h
y
l
a
t
i
o
n
(
%
)
CON
OHM
−231 −142 −133 −112 −70 −41
(d)
Figure 5: Maternal hyperglycemia increased rat promoter 1 CpG methylation in females. (a) Rat promoter 1 CpG methylation in females.
(b) Rat promoter 2 CpG methylation in females. (c) Rat promoter 1 CpG methylation in males. (d) Rat promoter 2 CpG methylation in
males. All data were expressed as mean percent of methylation ± standard error of the mean, n = 4C O Nf e m a l e ,n = 3 OHM female, n = 5
CON male, and n = 3 OHM male. ∗P<0.05.
4. Discussion
The most important ﬁnding of this study is that maternal
hyperglycemia decreased H3Me3K36 of the IGF-1 gene in
the same fashion that IUGR decreased this histone mark
[3]. This ﬁnding is most intriguing given that both maternal
hyperglycemia and IUGR have the same phenotype of adult
onset insulin resistance. We speculate that H3Me3K36 of the
IGF-1 gene is sensitive to the glucose level of the prenatal
environment, with resultant alteration of IGF-1 mRNA
expression and ultimately vulnerability to adult onset insulin
resistance.
MaternalhyperglycemiadecreasedhepaticH3Me3K36of
the IGF-1 gene in DOL 21 OHM males. This histone mark
is often associated with mRNA elongation and actively tran-
scribed genes [7–9]. The protein that places the H3Me3K36
mark, one example of which is Wolf-Hirschhorn Syndrome
Candidate 1, associates itself with RNA polymerase 2, the
enzyme responsible for mRNA transcription, and thus
inﬂuences mRNA levels [9, 16]. H3Me3K36 appears to
be particularly sensitive to alteration by glucose given the
similarity of ﬁndings between our study of OHM and of
IUGR [3]. Decreased H3Me3K36 of the IGF-1 gene occurred
in both genders in our prior study of IUGR, and these
ﬁndingswereassociatedwithdecreasedIGF-1mRNAvariant
levels and adult onset insulin resistance in both genders
[3, 17].
H3Me3K36 decreases in the setting of either increased
or decreased glucose [3]. One possible explanation is that
H3Me3K36 is not sensitive to glucose levels themselves but
rather other alterations seen in the setting of both maternal
hyperglycemia and IUGR, including acidosis and hypoxia.
Maternal hyperglycemia leads to fetal acidosis and hypoxia
resulting from the increased metabolic activity associated
with excess nutrient delivery [18]. IUGR leads to fetal
acidosis and hypoxia through decreased nutrient and oxygen
delivery from UPI.
Decreased H3Me3K36 of the IGF-1 gene is consistent
with the ﬁnding of decreased IGF-1 mRNA variant levels in
males. Large males from hyperglycemic dams subsequently
donotgainweightasquicklyandha v elo werglucoselev elsby
2monthsofagecomparedtotheircontrolcounterparts[10],
a ﬁnding which is preceded by decreased IGF-1 mRNA levels
inmaleoﬀspring.ThisﬁndingsuggestsdecreasedmaleIGF-1
mRNA levels as one mechanism through which large male
oﬀspring develop insulin resistance and postnatal growth
restriction.6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Of note, although maternal hyperglycemia decreases
hepatic H3Me3K36 in males, few gender diﬀerences were
seen in the CON oﬀspring. For example, histone acetylation,
also a marker for gene activation [19] ,o fI G F - 1P 2i si n -
creased relative to P1 beyond the neonatal period in both
genders, a ﬁnding seen in other studies [3, 20]. Increased P2
histone acetylation beyond the neonatal period may be an
eﬀect of growth hormone signaling [21, 22]. The similarity
in histone acetylation and methylation markers and mRNA
variantlevelsoccurredincontrolanimalsdespitehousingthe
animals in diﬀerent locations and utilizing diﬀerent control
interventions. Similarities that exist in the control animal
histone code along IGF-1 reinforced the normal pattern of
H3 acetylation and methylation along the IGF-1 gene.
DNA methylation of IGF-1 promoters 1 and 2 remains
unchanged in males and is increased in females in this
study. DNA methylation is a factor in driving histone code
changes [4,5].DNAmethylationmayalsoaidinnucleosome
positioning and thereby eﬀect mRNA transcription [5].
Nucleosomes are approximately 150 base pairs in length,
and we found an approximately 150 base pair region of P1
that had less methylation than either 5  or 3  of this region
in both genders. Thus the increase in DNA methylation in
female DOL 21 OHM may contribute to decreased female
IGF-1 mRNA variant levels that did not reach statistical
signiﬁcance.
Maternal hyperglycemia did not change serum IGF-1
levels in DOL 21 OHM. IGF-1 serum levels are still present
in the setting of decreased or absent hepatic IGF-1 mRNA
production, such as the IGF-1 mouse knockout model [2].
The ability of the IGF-1 knockout to maintain serum IGF-1
levels can be achieved through a variety of IGF-1 binding
proteins which hold IGF-1 within the serum and may
contributetothenormalserumIGF-1levelsinourstudy[2].
Further, IGF-1 often acts through a paracrine fashion, and
thus the importance of decreased IGF-1 mRNA variant levels
is in the ability to ﬁne tune IGF-1 expression and may not be
reﬂected completely in serum IGF-1 levels.
One limitation of this study is that maternal hyper-
glycemia was induced by STZ, and it is possible that STZ
crosses the placenta and thus aﬀects fetal and postnatal
glucoselevels,hepaticIGF-1mRNAvariantlevels,andepige-
netic characteristics. However, maternal hyperglycemia did
not increase glucose levels at DOL 21, indicating that few,
if any, oﬀspring pancreatic beta cells were aﬀected directly
by STZ. It is also unlikely that STZ directly aﬀected hepatic
IGF-1 mRNA variant levels and epigenetic characteristics
because STZ is not known to eﬀect the hepatocyte. A further
limitation is the small n used in this study. However, despite
the small n we were able to see signiﬁcant changes in the
epigenetic proﬁle of IGF-1 and are consistent with results
seen by Fu et al. in the setting of IUGR [3].
In conclusion, maternal hyperglycemia decreases DOL
21 male rat oﬀspring hepatic IGF-1 mRNA variant levels
and H3Me3K36 of the IGF-1 gene. These ﬁndings are most
intriguing given that IUGR also decreases hepatic IGF-1
mRNA variant levels and H3Me3K36 of the IGF-1 gene, and
both maternal hyperglycemia and IUGR increase the risk
of the same outcome of adult onset insulin resistance. We
speculate that decreased H3Me3K36 of the IGF-1 gene in
both maternal hyperglycemia and IUGR leads to decreased
IGF-1 mRNA variant levels and contributes to the develop-
ment of adult onset insulin resistance.
Abbreviations
I G F - 1 : I n s u l i nl i k eg r o w t hf a c t o r1
IUGR: Intrauterine growth restriction
OHM: Oﬀspring of hyperglycemic mothers
DOL: Day of life
ChIP: Chromatin immunoprecipitation
H3Me3K36: Histone 3 trimethylation of lysine 36
H3AcK14: Histone 3 acetylation of lysine 14
H3Me2K4: Histone 3 dimethylation of lysine 4
H3Me3K4: Histone 3 trimethylation of lysine 4
UTR: Untranslated region.
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